UK Nod For Pfizer’s COVID-19 Oral Treatment
Pfizer Aims For Early 2022 To Deliver First Treatment Courses To Great Britain
Executive Summary
Pfizer’s Paxlovid is the second take-at-home COVID-19 treatment approved for use in the UK.
You may also be interested in...
EU Approves Paxlovid For COVID-19
The European Medicines Agency’s assessment of the oral antiviral combination was conducted under the OPEN Initiative, which involves information sharing among international regulators.
Coronavirus Notebook: Pfizer Files Paxlovid In EU, France Updates Treatment Advice As Omicron Proliferates
NRx Pharmaceuticals has again filed for a US emergency use authorization for aviptadil, this time for critically ill patients with no other options. The UK has said that there is currently no need to give a second booster vaccine.
Merck & Co Makes Case For Molnupiravir After Narrow FDA Nod
US regulators have granted emergency authorization to the antiviral molnupiravir but only for use when "alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate."